ADVENTRX Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates for the treatment of cancer. Its lead product candidates include ANX-530, a novel emulsion formulations of chemotherapy drug vinorelbine to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin and advanced or metastatic breast cancer; and ANX-514, a novel emulsion formulation of the chemotherapy drug docetaxel for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers. ADVENTRX Pharmaceuticals also holds rights of other compounds that the company is evaluating for future preclinical and clinical development, including ANX-015, a novel formulation of clarithromycin for the treatment of mild to moderate bacterial infections, such as community-acquired pneumonia; ANX-016, an intravenous formulation of vancomycin to treat gram-positive bacterial infections; and ANX-201, a member of a new class of reverse transcriptase inhibitor for a spectrum of antiviral activity against human immunodeficiency virus, human and avian influenza viruses, and herpes simplex viruses. In addition, its other compounds comprise ANX-211, a spectrum antiviral agent formulated to provide antiviral activity against multiple strains of virus; ANX-510, a folate-based biomodulator designed to replace leucovorin as the preferred method to enhance the activity and reduce the associated toxicity of cancer chemotherapeutic agent 5-fluorouracil; ANX-513, a novel formulation of paclitaxel to reduce the need for immunosuppressant premedication associated with administration of Taxol; and ANX-575, a novel formulation of alpha-tocopheryl succinate to facilitate cell death in cancer cells. The company was founded in 1995 is based in San Diego, California.
|
